FimeaWeb
Tällä hakulomakkeella voit hakea tiettyä lääkettä tai lääkeainetta, tai luoda listoja haluamillasi tarkemmilla hakuehdoilla.
Product name
3-Sulfa
Marketing authorisation holder
NEOFARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
G01AE10 combinations of sulfonamides, All medicinal products belonging to the ATC group
Prescription status
Prescription
Pharmaceutical form
pessary
Pharmaceutical form
pessary
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
8275
Marketing authorisation date
06.01.1982
MA withdrawal date
06.01.1989
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
3-Sulfa
Marketing authorisation holder
NEOFARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
G01AE10 combinations of sulfonamides, All medicinal products belonging to the ATC group
Prescription status
Prescription
Pharmaceutical form
vaginal ointment
Pharmaceutical form
vaginal ointment
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
6889
Marketing authorisation date
28.08.1974
MA withdrawal date
28.08.1988
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A T 10
Marketing authorisation holder
BAYER AG
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
A11CC02 dihydrotachysterol, All medicinal products belonging to the ATC group
Strength
1 mg/ml
Prescription status
Prescription
Pharmaceutical form
drops
Active substances
Dihydrotachysterol
Pharmaceutical form
drops
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
6232
Marketing authorisation date
30.06.1971
MA withdrawal date
30.06.1991
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Mastin Vet
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
QJ51CA01 ampicillin, All medicinal products belonging to the ATC group
Prescription status
Prescription
Pharmaceutical form
intramammary injection
Active substances
Ampicillin trihydrate
Pharmaceutical form
intramammary injection
Type
Veterinary medicinal product
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
6327
Marketing authorisation date
09.02.1972
MA withdrawal date
09.02.1999
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Pen
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01CA01 ampicillin, All medicinal products belonging to the ATC group
Prescription status
Prescription
Pharmaceutical form
powder for infusion
Active substances
Ampicillin sodium
Pharmaceutical form
powder for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
8126
Marketing authorisation date
01.04.1981
MA withdrawal date
01.04.1992
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Pen
Marketing authorisation holder
ORION CORPORATION
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01CA01 ampicillin, All medicinal products belonging to the ATC group
Substitution group
2666
Old product names
Strength
1 g
Prescription status
Prescription: 5 x 1 g
Pharmaceutical form
powder for solution for injection/infusion
Active substances
Ampicillin sodium
Pharmaceutical form
powder for solution for injection/infusion
Package size
Marketed: 5 x 1 g (Nordic article number: 583286)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
34711
Marketed status
Marketed: 5 x 1 g
Marketing authorisation date
24.11.2017
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Pen
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01CA01 ampicillin, All medicinal products belonging to the ATC group
Strength
50 mg/ml
Prescription status
Prescription
Pharmaceutical form
granules for oral liquid
Active substances
Ampicillin trihydrate
Pharmaceutical form
granules for oral liquid
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
6317
Marketing authorisation date
05.01.1972
MA withdrawal date
05.01.1988
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Pen
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01CA01 ampicillin, All medicinal products belonging to the ATC group
Strength
250 mg
Prescription status
Prescription
Pharmaceutical form
tablet
Active substances
Ampicillin trihydrate
Pharmaceutical form
tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
6773
Marketing authorisation date
03.04.1974
MA withdrawal date
03.04.1992
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Pen
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01CA01 ampicillin, All medicinal products belonging to the ATC group
Strength
500 mg
Prescription status
Prescription
Pharmaceutical form
tablet
Active substances
Ampicillin trihydrate
Pharmaceutical form
tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
5956
Marketing authorisation date
19.12.1969
MA withdrawal date
19.12.1991
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Pen
Marketing authorisation holder
ORION CORPORATION
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01CA01 ampicillin, All medicinal products belonging to the ATC group
Substitution group
2803
Old product names
Strength
500 mg
Prescription status
Prescription: 5 x 500 mg
Pharmaceutical form
powder for solution for injection/infusion
Active substances
Ampicillin sodium
Pharmaceutical form
powder for solution for injection/infusion
Package size
Marketed: 5 x 500 mg (Nordic article number: 583260)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
6507
Marketed status
Marketed: 5 x 500 mg
Marketing authorisation date
07.02.1973
Renewal date
07.03.2007
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Vita
Marketing authorisation holder
TAKEDA OY
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
R01AX02 retinol, All medicinal products belonging to the ATC group
Prescription status
Self-medication
Pharmaceutical form
nasal drops, solution
Pharmaceutical form
nasal drops, solution
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
6328
Marketing authorisation date
09.02.1972
Renewal date
11.09.2006
MA withdrawal date
28.02.2018
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Vitamiini Leiras
Marketing authorisation holder
OY LEIRAS FINLAND AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
D10AD02 retinol, All medicinal products belonging to the ATC group
Strength
5000 IU/g
Prescription status
Self-medication
Pharmaceutical form
cream
Active substances
Retinol palmitate
Pharmaceutical form
cream
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
3525
Marketing authorisation date
25.05.1966
Renewal date
12.05.2000
MA withdrawal date
17.03.2004
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
A-Vitamiini Lotion
Marketing authorisation holder
SCHERING OY
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
D10AD02 retinol, All medicinal products belonging to the ATC group
Strength
5000 IU/g
Prescription status
Self-medication
Pharmaceutical form
liniment
Active substances
Retinol palmitate
Pharmaceutical form
liniment
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
9285
Marketing authorisation date
11.06.1986
MA withdrawal date
11.06.1993
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abacavir Accord
Marketing authorisation holder
ACCORD HEALTHCARE B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AF06 abacavir, All medicinal products belonging to the ATC group
Substitution group
1253
Strength
300 mg
Prescription status
Prescription: 60 Not marketed: 120, 30, 60, 90
Pharmaceutical form
film-coated tablet
Active substances
Abacavir
Pharmaceutical form
film-coated tablet
Package size
Marketed: 60 (Nordic article number: 540418) Not marketed: 120, 30, 60, 90
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
37361
Marketed status
Marketed: 60 Not marketed: 120, 30, 60, 90
Marketing authorisation date
10.07.2020
Renewal date
23.12.2020
Prescription terms
HIV-infektion hoitoon perehtyneen lääkärin tulisi aloittaa hoito.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abacavir/Lamivudin Mylan
Parallel importer
PARANOVA OY
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Strength
600 mg / 300 mg
Prescription status
Prescription
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
37840
Marketing authorisation date
20.04.2020
MA withdrawal date
01.03.2021
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
Yes
Parallel distribution
No
Product name
Abacavir/Lamivudin Mylan
Marketing authorisation holder
MYLAN AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Substitution group
1245
Old product names
Abacavir/Lamivudine Mylan
Strength
600 mg / 300 mg
Prescription status
Not marketed: 30, 30 x 1, 60, 60 (2 x 30), 90, 90 (3 x 30)
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Package size
Not marketed: 30, 30 x 1, 60, 60 (2 x 30), 90, 90 (3 x 30)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
33010
Marketed status
Not marketed: 30, 30 x 1, 60, 60 (2 x 30), 90, 90 (3 x 30)
Marketing authorisation date
13.10.2016
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abacavir/Lamivudine Accord
Marketing authorisation holder
ACCORD HEALTHCARE B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Substitution group
1245
Old product names
Abacavir/Lamivudin Actavis
Iviverz
Strength
600 mg / 300 mg
Prescription status
Not marketed: 30, 90 (3 x 30)
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Package size
Not marketed: 30, 90 (3 x 30)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
33392
Marketed status
Not marketed: 30, 90 (3 x 30)
Marketing authorisation date
08.07.2016
Renewal date
30.08.2021
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abacavir/Lamivudine Sandoz
Parallel importer
ORIFARM OY
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Substitution group
1245
Strength
600 mg / 300 mg
Prescription status
Not marketed: 30
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Package size
Not marketed: 30
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
37463
Marketed status
Not marketed: 30
Marketing authorisation date
25.10.2019
Renewal date
07.03.2024
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
Yes
Parallel distribution
No
Product name
Abacavir/Lamivudine Sandoz
Marketing authorisation holder
SANDOZ A/S
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Substitution group
1245
Strength
600 mg / 300 mg
Prescription status
Prescription
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
33005
Marketing authorisation date
23.09.2016
Renewal date
17.12.2020
MA withdrawal date
03.10.2024
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abacavir/Lamivudine Stada
Marketing authorisation holder
STADA ARZNEIMITTEL AG
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Substitution group
1245
Old product names
Abacavir/Lamivudine Pharos
Strength
600 mg / 300 mg
Prescription status
Prescription: 30 Not marketed: 30, 90 (3 x 30)
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Package size
Marketed: 30 (Nordic article number: 444643) Not marketed: 30, 90 (3 x 30)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
33761
Marketed status
Marketed: 30 Not marketed: 30, 90 (3 x 30)
Marketing authorisation date
08.07.2016
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abacavir/Lamivudine Teva
Marketing authorisation holder
TEVA B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Strength
600 mg / 300 mg
Prescription status
Prescription
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
33088
Marketing authorisation date
23.06.2016
MA withdrawal date
08.03.2018
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abakavir/Lamivudin Mylan Pharma
Marketing authorisation holder
MYLAN AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group
Substitution group
1245
Old product names
Abakaviiri/Lamivudiini Vale
Abakavir/Lamivudin Vale
Strength
600 mg / 300 mg
Prescription status
Prescription: 30 Not marketed: 30, 30 x 1, 90, 90 (30 x 3)
Pharmaceutical form
film-coated tablet
Pharmaceutical form
film-coated tablet
Package size
Marketed: 30 (Nordic article number: 380961) Not marketed: 30, 30 x 1, 90, 90 (30 x 3)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
33936
Marketed status
Marketed: 30 Not marketed: 30, 30 x 1, 90, 90 (30 x 3)
Marketing authorisation date
11.10.2018
Prescription terms
Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abalgin
Marketing authorisation holder
ALTERNOVA A/S
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
N02AC04 dextropropoxyphene, All medicinal products belonging to the ATC group
Strength
65 mg
Prescription status
Prescription
Pharmaceutical form
capsule, hard
Active substances
Dextropropoxyphene hydrochloride
Pharmaceutical form
capsule, hard
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
1886
Marketing authorisation date
07.07.1965
Renewal date
22.02.2008
MA withdrawal date
05.02.2010
New active substance
No
Affecting the ability to drive
Yes
PKV
PA, PKV-lääke. Vain säilytettävällä reseptillä.
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abalgin Retard
Marketing authorisation holder
ALTERNOVA A/S
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
N02AC04 dextropropoxyphene, All medicinal products belonging to the ATC group
Strength
150 mg
Prescription status
Prescription
Pharmaceutical form
prolonged-release capsule, hard
Active substances
Dextropropoxyphene hydrochloride
Pharmaceutical form
prolonged-release capsule, hard
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
5297
Marketing authorisation date
03.04.1968
Renewal date
22.02.2008
MA withdrawal date
05.02.2010
New active substance
No
Affecting the ability to drive
Yes
PKV
PA, PKV-lääke. Vain säilytettävällä reseptillä.
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
ABASAGLAR
Marketing authorisation holder
ELI LILLY NEDERLAND B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
A10AE04 insulin glargine, All medicinal products belonging to the ATC group
Old product names
Abasria
Strength
100 U/ml
Prescription status
Prescription: 5 x 3 ml Not marketed: 10 x 3 ml
Pharmaceutical form
solution for injection in cartridge
Active substances
Insulin glargine
Biosimilar status
Biosimilaari
Biosimilar group
G006
Pharmaceutical form
solution for injection in cartridge
Package size
Marketed: 5 x 3 ml (Nordic article number: 138421) Not marketed: 10 x 3 ml
Type
Medicinal product for human use
Suitability for the elderly
A (Insulin glargine) Suitable for older adults. Avoidance of hypoglycaemia is of paramount importance. (updated 27.9.2021)
High-Risk Medicines Classification
More information about the National High-Risk Medicines Classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
EU/1/14/944/003,009
Marketed status
Marketed: 5 x 3 ml Not marketed: 10 x 3 ml
Marketing authorisation date
09.09.2014
Renewal date
25.07.2019
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
Yes
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
ABASAGLAR KwikPen
Marketing authorisation holder
ELI LILLY NEDERLAND B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
A10AE04 insulin glargine, All medicinal products belonging to the ATC group
Old product names
Abasria
Abasria Kwikpen
Abasaglar Kwikpen
Abasaglar
Strength
100 U/ml
Prescription status
Prescription: 2 x (5 x 3 ml) Prescription: 5 x 3 ml Not marketed: 2 x (5 x 3 ml), 5 x 3 ml
Pharmaceutical form
solution for injection in pre-filled pen
Active substances
Insulin glargine
Biosimilar status
Biosimilaari
Biosimilar group
G006
Pharmaceutical form
solution for injection in pre-filled pen
Package size
Marketed: 2 x (5 x 3 ml) (Nordic article number: 451991), 5 x 3 ml (Nordic article number: 448060) Not marketed: 2 x (5 x 3 ml), 5 x 3 ml
Type
Medicinal product for human use
Suitability for the elderly
A (Insulin glargine) Suitable for older adults. Avoidance of hypoglycaemia is of paramount importance. (updated 27.9.2021)
High-Risk Medicines Classification
More information about the National High-Risk Medicines Classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
EU/1/14/944/007-008,012-013
Marketed status
Marketed: 2 x (5 x 3 ml), 5 x 3 ml Not marketed: 2 x (5 x 3 ml), 5 x 3 ml
Marketing authorisation date
09.09.2014
Renewal date
25.07.2019
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
Yes
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
ABASAGLAR Tempo Pen
Marketing authorisation holder
ELI LILLY NEDERLAND B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
A10AE04 insulin glargine, All medicinal products belonging to the ATC group
Strength
100 U/ml
Prescription status
Not marketed: 2 x (5 x 3 ml), 5 x 3 ml
Pharmaceutical form
solution for injection in pre-filled pen
Active substances
Insulin glargine
Biosimilar status
Biosimilaari
Biosimilar group
G006
Pharmaceutical form
solution for injection in pre-filled pen
Package size
Not marketed: 2 x (5 x 3 ml), 5 x 3 ml
Type
Medicinal product for human use
Suitability for the elderly
A (Insulin glargine) Suitable for older adults. Avoidance of hypoglycaemia is of paramount importance. (updated 27.9.2021)
High-Risk Medicines Classification
More information about the National High-Risk Medicines Classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
EU/1/14/944/014-015
Marketed status
Not marketed: 2 x (5 x 3 ml), 5 x 3 ml
Marketing authorisation date
23.07.2020
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
Yes
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abbodop
Marketing authorisation holder
HOSPIRA ENTERPRISES BV
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
C01CA04 dopamine, All medicinal products belonging to the ATC group
Strength
1 mg/ml
Prescription status
Prescription
Pharmaceutical form
solution for infusion
Active substances
Dopamine hydrochloride
Pharmaceutical form
solution for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
10647
Marketing authorisation date
12.02.1992
Renewal date
27.08.2007
MA withdrawal date
31.10.2009
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abbodop
Marketing authorisation holder
HOSPIRA ENTERPRISES BV
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
C01CA04 dopamine, All medicinal products belonging to the ATC group
Strength
2 mg/ml
Prescription status
Prescription
Pharmaceutical form
solution for infusion
Active substances
Dopamine hydrochloride
Pharmaceutical form
solution for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
10648
Marketing authorisation date
12.02.1992
Renewal date
27.08.2007
MA withdrawal date
31.10.2009
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abbokinase
Marketing authorisation holder
ABBOTT FRANCE S.A.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
B01AD04 urokinase, All medicinal products belonging to the ATC group
Prescription status
Prescription
Pharmaceutical form
powder for infusion
Active substances
Urokinase
Pharmaceutical form
powder for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
8726
Marketing authorisation date
18.04.1984
MA withdrawal date
18.04.1985
Prescription terms
Vain sairaalakäyttöön.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abbonate
Marketing authorisation holder
ABBOXIA AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
N06AF04 tranylcypromine, All medicinal products belonging to the ATC group
Strength
20 mg
Prescription status
Not marketed: 105, 30, 60, 90
Pharmaceutical form
film-coated tablet
Active substances
Tranylcypromine sulphate
Pharmaceutical form
film-coated tablet
Package size
Not marketed: 105, 30, 60, 90
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
43023
Marketed status
Not marketed: 105, 30, 60, 90
Marketing authorisation date
13.06.2024
Prescription terms
Hoidon aloittaa ja sitä valvoo psykiatri.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Old product names
Erythrocin
Prescription status
Prescription
Pharmaceutical form
powder for injection
Active substances
Erythromycin lactobionate
Pharmaceutical form
powder for injection
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
1285
Marketing authorisation date
14.04.1965
MA withdrawal date
14.04.1986
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Parallel importer
ORIFARM OY
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Substitution group
1859
Old product names
Strength
1 g
Prescription status
Prescription: 1 g Not marketed: 1 g
Pharmaceutical form
powder for solution for infusion
Active substances
Erythromycin lactobionate
Pharmaceutical form
powder for solution for infusion
Package size
Marketed: 1 g (Nordic article number: 467014) Not marketed: 1 g
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
35021
Marketed status
Marketed: 1 g Not marketed: 1 g
Marketing authorisation date
29.03.2017
Renewal date
07.09.2021
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
Yes
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
AMDIPHARM LIMITED
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Substitution group
1859
Strength
1 g
Prescription status
Prescription: 1 g
Pharmaceutical form
powder for solution for infusion
Active substances
Erythromycin lactobionate
Pharmaceutical form
powder for solution for infusion
Package size
Marketed: 1 g (Nordic article number: 405001)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
9143
Marketed status
Marketed: 1 g
Marketing authorisation date
30.10.1985
Renewal date
15.11.2007
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
40 mg/ml
Prescription status
Prescription
Pharmaceutical form
granules for oral liquid
Active substances
Erythromycin ethylsuccinate
Pharmaceutical form
granules for oral liquid
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
8485
Marketing authorisation date
20.04.1983
Renewal date
21.10.1998
MA withdrawal date
20.04.1999
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT LABORATORIES
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
40 mg/ml
Prescription status
Prescription
Pharmaceutical form
granules for oral liquid
Active substances
Erythromycin ethylsuccinate
Pharmaceutical form
granules for oral liquid
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
7926
Marketing authorisation date
16.04.1980
MA withdrawal date
16.04.1984
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
100 mg/ml
Prescription status
Prescription
Pharmaceutical form
granules for oral suspension
Active substances
Erythromycin ethylsuccinate
Pharmaceutical form
granules for oral suspension
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
9222
Marketing authorisation date
05.02.1986
Renewal date
26.04.2002
MA withdrawal date
05.02.2003
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
250 mg
Prescription status
Prescription
Pharmaceutical form
film-coated tablet
Active substances
Erythromycin stearate
Pharmaceutical form
film-coated tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
8486
Marketing authorisation date
20.04.1983
Renewal date
26.04.2002
MA withdrawal date
20.04.2003
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT LABORATORIES
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
250 mg
Prescription status
Prescription
Pharmaceutical form
tablet
Active substances
Erythromycin stearate
Pharmaceutical form
tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
7927
Marketing authorisation date
16.04.1980
MA withdrawal date
16.04.1984
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
400 mg
Prescription status
Prescription
Pharmaceutical form
single-dose granules
Active substances
Erythromycin ethylsuccinate
Pharmaceutical form
single-dose granules
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
9064
Marketing authorisation date
31.07.1985
MA withdrawal date
31.07.1989
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT LABORATORIES
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Old product names
Erythrocin
Strength
500 mg
Prescription status
Prescription
Pharmaceutical form
tablet
Active substances
Erythromycin stearate
Pharmaceutical form
tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
7456
Marketing authorisation date
17.08.1977
MA withdrawal date
17.08.1983
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
500 mg
Prescription status
Prescription
Pharmaceutical form
film-coated tablet
Active substances
Erythromycin stearate
Pharmaceutical form
film-coated tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
8487
Marketing authorisation date
20.04.1983
Renewal date
26.04.2002
MA withdrawal date
20.04.2005
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin Novum
Marketing authorisation holder
AMDIPHARM LIMITED
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
500 mg
Prescription status
Not marketed: 30, 40
Pharmaceutical form
film-coated tablet
Active substances
Erythromycin ethylsuccinate
Pharmaceutical form
film-coated tablet
Package size
Not marketed: 30, 40 (Nordic article number: 004721)
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
12860
Marketed status
Not marketed: 30, 40
Marketing authorisation date
23.03.1998
Renewal date
15.11.2007
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin Novum
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
500 mg
Prescription status
Prescription
Pharmaceutical form
tablet
Active substances
Erythromycin ethylsuccinate
Pharmaceutical form
tablet
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
9663
Marketing authorisation date
11.05.1988
MA withdrawal date
11.05.1997
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abboticin-Natriumklorid
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J01FA01 erythromycin, All medicinal products belonging to the ATC group
Strength
1 g/250 ml
Prescription status
Prescription
Pharmaceutical form
powder for infusion
Active substances
Erythromycin lactobionate
Pharmaceutical form
powder for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
10229
Marketing authorisation date
06.06.1990
MA withdrawal date
06.06.1991
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abdoscan
Marketing authorisation holder
AMERSHAM HEALTH AS
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
V08CB02 ferristene, All medicinal products belonging to the ATC group
Strength
23.4 mg Fe
Prescription status
Prescription
Pharmaceutical form
granules for oralsuspension / rectal suspension
Active substances
Dynospheres M 35
Pharmaceutical form
granules for oralsuspension / rectal suspension
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
11483
Marketing authorisation date
06.06.1994
Renewal date
31.05.1999
MA withdrawal date
06.06.2000
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abecma
Marketing authorisation holder
BRISTOL-MYERS SQUIBB PHARMA EEIG
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
L01XL07 idecabtagene vicleucel, All medicinal products belonging to the ATC group
Strength
260-500 x 10exp6 solua
Prescription status
Not marketed: max 100 ml
Pharmaceutical form
dispersion for infusion
Active substances
Idecabtagene vicleucel
Pharmaceutical form
dispersion for infusion
Package size
Not marketed: max 100 ml
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
EU/1/21/1539/001
Marketed status
Not marketed: max 100 ml
Marketing authorisation date
18.08.2021
Renewal date
08.06.2023
Prescription terms
CAR-T-soluhoito annetaan kvalifioidussa hoitokeskuksessa hematologisten syöpien hoitoon perehtyneen ja CAR-T-soluhoitojen antamiseen koulutetun lääkärin ohjauksessa ja valvonnassa.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
Yes
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abelcet
Marketing authorisation holder
TEVA PHARMA B.V.
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J02AA01 amphotericin, All medicinal products belonging to the ATC group
Strength
5 mg/ml
Prescription status
Prescription
Pharmaceutical form
concentrate for suspension for infusion
Active substances
Amphotericin
Pharmaceutical form
concentrate for suspension for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
11994
Marketing authorisation date
19.08.1996
Renewal date
02.05.2007
MA withdrawal date
01.04.2020
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Product name
Abelcet Lipid Complex
Parallel importer
PARANOVA OY
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
J02AA01 amphotericin, All medicinal products belonging to the ATC group
Old product names
Abelcet
Strength
5 mg/ml
Prescription status
Prescription
Pharmaceutical form
concentrate for dispersion for infusion
Active substances
Amphotericin
Pharmaceutical form
concentrate for dispersion for infusion
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa peruuntunut
MA-number
35019
Marketing authorisation date
31.05.2017
MA withdrawal date
01.07.2021
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
No
Plasma-derived products
No
Parallel import
Yes
Parallel distribution
No
Product name
Abevmy
Marketing authorisation holder
BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Shortage
No
Link to package leaflet
Link to·summary of product characteristics
ATC code
L01FG01 bevacizumab, All medicinal products belonging to the ATC group
Strength
25 mg/ml
Prescription status
Not marketed: 16 ml, 2 x 16 ml, 3 x 16 ml, 4 ml, 5 x 4 ml
Pharmaceutical form
concentrate for solution for infusion
Active substances
Bevacizumab
Biosimilar status
Biosimilaari
Biosimilar group
G015
Pharmaceutical form
concentrate for solution for infusion
Package size
Not marketed: 16 ml, 2 x 16 ml, 3 x 16 ml, 4 ml, 5 x 4 ml
Type
Medicinal product for human use
Suitability for the elderly
No classification
Marketing authorisation status
Myyntilupa myönnetty
MA-number
EU/1/20/1515/001-005
Marketed status
Not marketed: 16 ml, 2 x 16 ml, 3 x 16 ml, 4 ml, 5 x 4 ml
Marketing authorisation date
21.04.2021
Prescription terms
Valmistetta tulee käyttää vain syövän hoitoon perehtyneen lääkärin valvonnassa.
New active substance
No
Affecting the ability to drive
No
Biological medicinal products
Yes
Plasma-derived products
No
Parallel import
No
Parallel distribution
No
Search results
(0)
|
Search condition
|
Value
|
|---|
5
Showing 1-50/10000
Showing 1-50/10000
1.
Product name
3-Sulfa
Strength
Pharmaceutical form
pessary
Marketing authorisation holder
NEOFARMA
Link to package leaflet
2.
Product name
3-Sulfa
Strength
Pharmaceutical form
vaginal ointment
Marketing authorisation holder
NEOFARMA
Link to package leaflet
3.
Product name
A T 10
Strength
1 mg/ml
Pharmaceutical form
drops
Marketing authorisation holder
BAYER AG
Link to package leaflet
4.
Product name
A-Mastin Vet
Strength
Pharmaceutical form
intramammary injection
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Link to package leaflet
5.
Product name
A-Pen
Strength
Pharmaceutical form
powder for infusion
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Link to package leaflet
6.
Product name
A-Pen
Strength
1 g
Pharmaceutical form
powder for solution for injection/infusion
Marketing authorisation holder
ORION CORPORATION
Link to package leaflet
7.
Product name
A-Pen
Strength
50 mg/ml
Pharmaceutical form
granules for oral liquid
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Link to package leaflet
8.
Product name
A-Pen
Strength
250 mg
Pharmaceutical form
tablet
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Link to package leaflet
9.
Product name
A-Pen
Strength
500 mg
Pharmaceutical form
tablet
Marketing authorisation holder
ORION CORPORATION ORION PHARMA
Link to package leaflet
10.
Product name
A-Pen
Strength
500 mg
Pharmaceutical form
powder for solution for injection/infusion
Marketing authorisation holder
ORION CORPORATION
Link to package leaflet
11.
Product name
A-Vita
Strength
Pharmaceutical form
nasal drops, solution
Marketing authorisation holder
TAKEDA OY
Link to package leaflet
12.
Product name
A-Vitamiini Leiras
Strength
5000 IU/g
Pharmaceutical form
cream
Marketing authorisation holder
OY LEIRAS FINLAND AB
Link to package leaflet
13.
Product name
A-Vitamiini Lotion
Strength
5000 IU/g
Pharmaceutical form
liniment
Marketing authorisation holder
SCHERING OY
Link to package leaflet
14.
Product name
Abacavir Accord
Strength
300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
ACCORD HEALTHCARE B.V.
Link to package leaflet
15.
Product name
Abacavir/Lamivudin Mylan
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Parallel importer
PARANOVA OY
Link to package leaflet
16.
Product name
Abacavir/Lamivudin Mylan
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
MYLAN AB
Link to package leaflet
17.
Product name
Abacavir/Lamivudine Accord
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
ACCORD HEALTHCARE B.V.
Link to package leaflet
18.
Product name
Abacavir/Lamivudine Sandoz
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Parallel importer
ORIFARM OY
Link to package leaflet
19.
Product name
Abacavir/Lamivudine Sandoz
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
SANDOZ A/S
Link to package leaflet
20.
Product name
Abacavir/Lamivudine Stada
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
STADA ARZNEIMITTEL AG
Link to package leaflet
21.
Product name
Abacavir/Lamivudine Teva
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
TEVA B.V.
Link to package leaflet
22.
Product name
Abakavir/Lamivudin Mylan Pharma
Strength
600 mg / 300 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
MYLAN AB
Link to package leaflet
23.
Product name
Abalgin
Strength
65 mg
Pharmaceutical form
capsule, hard
Marketing authorisation holder
ALTERNOVA A/S
Link to package leaflet
24.
Product name
Abalgin Retard
Strength
150 mg
Pharmaceutical form
prolonged-release capsule, hard
Marketing authorisation holder
ALTERNOVA A/S
Link to package leaflet
25.
Product name
ABASAGLAR
Strength
100 U/ml
Pharmaceutical form
solution for injection in cartridge
Marketing authorisation holder
ELI LILLY NEDERLAND B.V.
Link to package leaflet
26.
Product name
ABASAGLAR KwikPen
Strength
100 U/ml
Pharmaceutical form
solution for injection in pre-filled pen
Marketing authorisation holder
ELI LILLY NEDERLAND B.V.
Link to package leaflet
27.
Product name
ABASAGLAR Tempo Pen
Strength
100 U/ml
Pharmaceutical form
solution for injection in pre-filled pen
Marketing authorisation holder
ELI LILLY NEDERLAND B.V.
Link to package leaflet
28.
Product name
Abbodop
Strength
1 mg/ml
Pharmaceutical form
solution for infusion
Marketing authorisation holder
HOSPIRA ENTERPRISES BV
Link to package leaflet
29.
Product name
Abbodop
Strength
2 mg/ml
Pharmaceutical form
solution for infusion
Marketing authorisation holder
HOSPIRA ENTERPRISES BV
Link to package leaflet
30.
Product name
Abbokinase
Strength
Pharmaceutical form
powder for infusion
Marketing authorisation holder
ABBOTT FRANCE S.A.
Link to package leaflet
31.
Product name
Abbonate
Strength
20 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
ABBOXIA AB
Link to package leaflet
32.
Product name
Abboticin
Strength
Pharmaceutical form
powder for injection
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Link to package leaflet
33.
Product name
Abboticin
Strength
1 g
Pharmaceutical form
powder for solution for infusion
Parallel importer
ORIFARM OY
Link to package leaflet
34.
Product name
Abboticin
Strength
1 g
Pharmaceutical form
powder for solution for infusion
Marketing authorisation holder
AMDIPHARM LIMITED
Link to package leaflet
35.
Product name
Abboticin
Strength
40 mg/ml
Pharmaceutical form
granules for oral liquid
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Link to package leaflet
36.
Product name
Abboticin
Strength
40 mg/ml
Pharmaceutical form
granules for oral liquid
Marketing authorisation holder
ABBOTT LABORATORIES
Link to package leaflet
37.
Product name
Abboticin
Strength
100 mg/ml
Pharmaceutical form
granules for oral suspension
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Link to package leaflet
38.
Product name
Abboticin
Strength
250 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Link to package leaflet
39.
Product name
Abboticin
Strength
250 mg
Pharmaceutical form
tablet
Marketing authorisation holder
ABBOTT LABORATORIES
Link to package leaflet
40.
Product name
Abboticin
Strength
400 mg
Pharmaceutical form
single-dose granules
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Link to package leaflet
41.
Product name
Abboticin
Strength
500 mg
Pharmaceutical form
tablet
Marketing authorisation holder
ABBOTT LABORATORIES
Link to package leaflet
42.
Product name
Abboticin
Strength
500 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
ABBOTT SCANDINAVIA AB
Link to package leaflet
43.
Product name
Abboticin Novum
Strength
500 mg
Pharmaceutical form
film-coated tablet
Marketing authorisation holder
AMDIPHARM LIMITED
Link to package leaflet
44.
Product name
Abboticin Novum
Strength
500 mg
Pharmaceutical form
tablet
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Link to package leaflet
45.
Product name
Abboticin-Natriumklorid
Strength
1 g/250 ml
Pharmaceutical form
powder for infusion
Marketing authorisation holder
ABBOTT LABORATORIES LTD.
Link to package leaflet
46.
Product name
Abdoscan
Strength
23.4 mg Fe
Pharmaceutical form
granules for oralsuspension / rectal suspension
Marketing authorisation holder
AMERSHAM HEALTH AS
Link to package leaflet
47.
Product name
Abecma
Strength
260-500 x 10exp6 solua
Pharmaceutical form
dispersion for infusion
Marketing authorisation holder
BRISTOL-MYERS SQUIBB PHARMA EEIG
Link to package leaflet
48.
Product name
Abelcet
Strength
5 mg/ml
Pharmaceutical form
concentrate for suspension for infusion
Marketing authorisation holder
TEVA PHARMA B.V.
Link to package leaflet
49.
Product name
Abelcet Lipid Complex
Strength
5 mg/ml
Pharmaceutical form
concentrate for dispersion for infusion
Parallel importer
PARANOVA OY
Link to package leaflet
50.
Product name
Abevmy
Strength
25 mg/ml
Pharmaceutical form
concentrate for solution for infusion
Marketing authorisation holder
BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Link to package leaflet
| Product name | Strength | Pharmaceutical form | Availability | Marketing authorisation holder | Active substance | ATC code and text | Biological medicinal products | Biosimilars | Veterinary medicinal product | Affecting the ability to drive | Medicinal product for human use | Herbal medicinal and homeopathic preparations | MA-number | Marketing authorisation date | MA withdrawal date | Prescription terms | Schengen | Package size | Self care package size | Plasma-derived products | PKV | Prescription status | Parallel import/distribution | New active substance | Medicine75+ | Marketing authorisation status / Registration status | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3-Sulfa | pessary | Not marketed | NEOFARMA |
Urea
(+3)
|
G01AE10 combinations of sulfonamides | No | No | No | No | Yes | No | 8275 | 06.01.1989 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | ||||||
| Product name | 3-Sulfa | ||||||||||||||||||||||||||
| Marketing authorisation holder | NEOFARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | G01AE10 combinations of sulfonamides, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | pessary | ||||||||||||||||||||||||||
| Active substances | Urea, Sulfabenzamide, Sulfacetamide, Sulfathiazole | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 8275 | ||||||||||||||||||||||||||
| Marketing authorisation date | 06.01.1982 | ||||||||||||||||||||||||||
| MA withdrawal date | 06.01.1989 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| 3-Sulfa | vaginal ointment | Not marketed | NEOFARMA |
Sulfabenzamide
(+2)
|
G01AE10 combinations of sulfonamides | No | No | No | No | Yes | No | 6889 | 28.08.1988 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | ||||||
| Product name | 3-Sulfa | ||||||||||||||||||||||||||
| Marketing authorisation holder | NEOFARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | G01AE10 combinations of sulfonamides, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | vaginal ointment | ||||||||||||||||||||||||||
| Active substances | Sulfabenzamide, Sulfacetamide, Sulfathiazole | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 6889 | ||||||||||||||||||||||||||
| Marketing authorisation date | 28.08.1974 | ||||||||||||||||||||||||||
| MA withdrawal date | 28.08.1988 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A T 10 | 1 mg/ml | drops | Not marketed | BAYER AG | Dihydrotachysterol |
A11CC02 dihydrotachysterol | No | No | No | No | Yes | No | 6232 | 30.06.1991 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | A T 10 | ||||||||||||||||||||||||||
| Marketing authorisation holder | BAYER AG | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | A11CC02 dihydrotachysterol, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 1 mg/ml | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | drops | ||||||||||||||||||||||||||
| Active substances | Dihydrotachysterol | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 6232 | ||||||||||||||||||||||||||
| Marketing authorisation date | 30.06.1971 | ||||||||||||||||||||||||||
| MA withdrawal date | 30.06.1991 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Mastin Vet | intramammary injection | Not marketed | ORION CORPORATION ORION PHARMA | Ampicillin trihydrate |
QJ51CA01 ampicillin | No | No | Yes | No | No | No | 6327 | 09.02.1999 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | ||||||
| Product name | A-Mastin Vet | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION ORION PHARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | QJ51CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | intramammary injection | ||||||||||||||||||||||||||
| Active substances | Ampicillin trihydrate | ||||||||||||||||||||||||||
| Type | Veterinary medicinal product | ||||||||||||||||||||||||||
| Target animal species | |||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 6327 | ||||||||||||||||||||||||||
| Marketing authorisation date | 09.02.1972 | ||||||||||||||||||||||||||
| MA withdrawal date | 09.02.1999 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Pen | powder for infusion | Not marketed | ORION CORPORATION ORION PHARMA | Ampicillin sodium |
J01CA01 ampicillin | No | No | No | No | Yes | No | 8126 | 01.04.1992 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | ||||||
| Product name | A-Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION ORION PHARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J01CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | powder for infusion | ||||||||||||||||||||||||||
| Active substances | Ampicillin sodium | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 8126 | ||||||||||||||||||||||||||
| Marketing authorisation date | 01.04.1981 | ||||||||||||||||||||||||||
| MA withdrawal date | 01.04.1992 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Pen | 1 g | powder for solution for injection/infusion | Marketed | ORION CORPORATION | Ampicillin sodium |
J01CA01 ampicillin | No | No | No | No | Yes | No | 34711 | 24.11.2017 | No | No | 5 x 1 g | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | A-Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J01CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 2666 | ||||||||||||||||||||||||||
| Old product names | |||||||||||||||||||||||||||
| Strength | 1 g | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 5 x 1 g |
||||||||||||||||||||||||||
| Pharmaceutical form | powder for solution for injection/infusion | ||||||||||||||||||||||||||
| Active substances | Ampicillin sodium | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 5 x 1 g (Nordic article number: 583286) |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 34711 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 5 x 1 g |
||||||||||||||||||||||||||
| Marketing authorisation date | 24.11.2017 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Pen | 50 mg/ml | granules for oral liquid | Not marketed | ORION CORPORATION ORION PHARMA | Ampicillin trihydrate |
J01CA01 ampicillin | No | No | No | No | Yes | No | 6317 | 05.01.1988 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | A-Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION ORION PHARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J01CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 50 mg/ml | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | granules for oral liquid | ||||||||||||||||||||||||||
| Active substances | Ampicillin trihydrate | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 6317 | ||||||||||||||||||||||||||
| Marketing authorisation date | 05.01.1972 | ||||||||||||||||||||||||||
| MA withdrawal date | 05.01.1988 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Pen | 250 mg | tablet | Not marketed | ORION CORPORATION ORION PHARMA | Ampicillin trihydrate |
J01CA01 ampicillin | No | No | No | No | Yes | No | 6773 | 03.04.1992 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | A-Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION ORION PHARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J01CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 250 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | tablet | ||||||||||||||||||||||||||
| Active substances | Ampicillin trihydrate | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 6773 | ||||||||||||||||||||||||||
| Marketing authorisation date | 03.04.1974 | ||||||||||||||||||||||||||
| MA withdrawal date | 03.04.1992 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Pen | 500 mg | tablet | Not marketed | ORION CORPORATION ORION PHARMA | Ampicillin trihydrate |
J01CA01 ampicillin | No | No | No | No | Yes | No | 5956 | 19.12.1991 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | A-Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION ORION PHARMA | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J01CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 500 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | tablet | ||||||||||||||||||||||||||
| Active substances | Ampicillin trihydrate | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 5956 | ||||||||||||||||||||||||||
| Marketing authorisation date | 19.12.1969 | ||||||||||||||||||||||||||
| MA withdrawal date | 19.12.1991 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Pen | 500 mg | powder for solution for injection/infusion | Marketed | ORION CORPORATION | Ampicillin sodium |
J01CA01 ampicillin | No | No | No | No | Yes | No | 6507 | 07.02.1973 | No | No | 5 x 500 mg | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | A-Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ORION CORPORATION | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J01CA01 ampicillin, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 2803 | ||||||||||||||||||||||||||
| Old product names | |||||||||||||||||||||||||||
| Strength | 500 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 5 x 500 mg |
||||||||||||||||||||||||||
| Pharmaceutical form | powder for solution for injection/infusion | ||||||||||||||||||||||||||
| Active substances | Ampicillin sodium | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 5 x 500 mg (Nordic article number: 583260) |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 6507 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 5 x 500 mg |
||||||||||||||||||||||||||
| Marketing authorisation date | 07.02.1973 | ||||||||||||||||||||||||||
| Renewal date | 07.03.2007 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Vita | nasal drops, solution | Not marketed | TAKEDA OY |
Menthol
(+1)
|
R01AX02 retinol | No | No | No | No | Yes | No | 6328 | 28.02.2018 | No | No | No | No | Self-medication |
No / No | No classification | Myyntilupa peruuntunut | ||||||
| Product name | A-Vita | ||||||||||||||||||||||||||
| Marketing authorisation holder | TAKEDA OY | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | R01AX02 retinol, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Self-medication |
||||||||||||||||||||||||||
| Pharmaceutical form | nasal drops, solution | ||||||||||||||||||||||||||
| Active substances | Menthol, Retinol palmitate | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 6328 | ||||||||||||||||||||||||||
| Marketing authorisation date | 09.02.1972 | ||||||||||||||||||||||||||
| Renewal date | 11.09.2006 | ||||||||||||||||||||||||||
| MA withdrawal date | 28.02.2018 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Vitamiini Leiras | 5000 IU/g | cream | Not marketed | OY LEIRAS FINLAND AB | Retinol palmitate |
D10AD02 retinol | No | No | No | No | Yes | No | 3525 | 17.03.2004 | No | No | No | No | Self-medication |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | A-Vitamiini Leiras | ||||||||||||||||||||||||||
| Marketing authorisation holder | OY LEIRAS FINLAND AB | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | D10AD02 retinol, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 5000 IU/g | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Self-medication |
||||||||||||||||||||||||||
| Pharmaceutical form | cream | ||||||||||||||||||||||||||
| Active substances | Retinol palmitate | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 3525 | ||||||||||||||||||||||||||
| Marketing authorisation date | 25.05.1966 | ||||||||||||||||||||||||||
| Renewal date | 12.05.2000 | ||||||||||||||||||||||||||
| MA withdrawal date | 17.03.2004 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| A-Vitamiini Lotion | 5000 IU/g | liniment | Not marketed | SCHERING OY | Retinol palmitate |
D10AD02 retinol | No | No | No | No | Yes | No | 9285 | 11.06.1993 | No | No | No | No | Self-medication |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | A-Vitamiini Lotion | ||||||||||||||||||||||||||
| Marketing authorisation holder | SCHERING OY | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | D10AD02 retinol, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 5000 IU/g | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Self-medication |
||||||||||||||||||||||||||
| Pharmaceutical form | liniment | ||||||||||||||||||||||||||
| Active substances | Retinol palmitate | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 9285 | ||||||||||||||||||||||||||
| Marketing authorisation date | 11.06.1986 | ||||||||||||||||||||||||||
| MA withdrawal date | 11.06.1993 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir Accord | 300 mg | film-coated tablet | Marketed | ACCORD HEALTHCARE B.V. | Abacavir |
J05AF06 abacavir | No | No | No | No | Yes | No | 37361 | 10.07.2020 | Yes | No | 30, 60, 90, 120, 30, 60, 90, 120 | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | Abacavir Accord | ||||||||||||||||||||||||||
| Marketing authorisation holder | ACCORD HEALTHCARE B.V. | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AF06 abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1253 | ||||||||||||||||||||||||||
| Strength | 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 60 Not marketed: 120, 30, 60, 90 |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Abacavir | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 60 (Nordic article number: 540418) Not marketed: 120, 30, 60, 90 |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 37361 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 60 Not marketed: 120, 30, 60, 90 |
||||||||||||||||||||||||||
| Marketing authorisation date | 10.07.2020 | ||||||||||||||||||||||||||
| Renewal date | 23.12.2020 | ||||||||||||||||||||||||||
| Prescription terms | HIV-infektion hoitoon perehtyneen lääkärin tulisi aloittaa hoito. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudin Mylan | 600 mg / 300 mg | film-coated tablet | Not marketed | PARANOVA OY |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 37840 | 01.03.2021 | Yes | No | No | No | Prescription |
Yes / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | Abacavir/Lamivudin Mylan | ||||||||||||||||||||||||||
| Parallel importer | PARANOVA OY | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir hydrochloride | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 37840 | ||||||||||||||||||||||||||
| Marketing authorisation date | 20.04.2020 | ||||||||||||||||||||||||||
| MA withdrawal date | 01.03.2021 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | Yes | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudin Mylan | 600 mg / 300 mg | film-coated tablet | Not marketed | MYLAN AB |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 33010 | 13.10.2016 | Yes | No | 60, 90, 30, 30, 60 (2 x 30), 90 (3 x 30), 30 x 1, 30, 60, 60 (2 x 30), 90, 90 (3 x 30) | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | Abacavir/Lamivudin Mylan | ||||||||||||||||||||||||||
| Marketing authorisation holder | MYLAN AB | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1245 | ||||||||||||||||||||||||||
| Old product names | Abacavir/Lamivudine Mylan |
||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Not marketed: 30, 30 x 1, 60, 60 (2 x 30), 90, 90 (3 x 30) |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir hydrochloride | ||||||||||||||||||||||||||
| Package size (by package size) |
Not marketed: 30, 30 x 1, 60, 60 (2 x 30), 90, 90 (3 x 30) |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 33010 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Not marketed: 30, 30 x 1, 60, 60 (2 x 30), 90, 90 (3 x 30) |
||||||||||||||||||||||||||
| Marketing authorisation date | 13.10.2016 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudine Accord | 600 mg / 300 mg | film-coated tablet | Not marketed | ACCORD HEALTHCARE B.V. |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 33392 | 08.07.2016 | Yes | No | 30, 90 (3 x 30), 30 | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | Abacavir/Lamivudine Accord | ||||||||||||||||||||||||||
| Marketing authorisation holder | ACCORD HEALTHCARE B.V. | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1245 | ||||||||||||||||||||||||||
| Old product names | Abacavir/Lamivudin Actavis Iviverz |
||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Not marketed: 30, 90 (3 x 30) |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir | ||||||||||||||||||||||||||
| Package size (by package size) |
Not marketed: 30, 90 (3 x 30) |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 33392 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Not marketed: 30, 90 (3 x 30) |
||||||||||||||||||||||||||
| Marketing authorisation date | 08.07.2016 | ||||||||||||||||||||||||||
| Renewal date | 30.08.2021 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudine Sandoz | 600 mg / 300 mg | film-coated tablet | Not marketed | ORIFARM OY |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 37463 | 25.10.2019 | Yes | No | 30 | No | No | Prescription |
Yes / No | No classification | Myyntilupa myönnetty | ||||
| Product name | Abacavir/Lamivudine Sandoz | ||||||||||||||||||||||||||
| Parallel importer | ORIFARM OY | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1245 | ||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Not marketed: 30 |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir hydrochloride | ||||||||||||||||||||||||||
| Package size (by package size) |
Not marketed: 30 |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 37463 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Not marketed: 30 |
||||||||||||||||||||||||||
| Marketing authorisation date | 25.10.2019 | ||||||||||||||||||||||||||
| Renewal date | 07.03.2024 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | Yes | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudine Sandoz | 600 mg / 300 mg | film-coated tablet | Not marketed | SANDOZ A/S |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 33005 | 03.10.2024 | Yes | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | Abacavir/Lamivudine Sandoz | ||||||||||||||||||||||||||
| Marketing authorisation holder | SANDOZ A/S | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1245 | ||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir hydrochloride | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 33005 | ||||||||||||||||||||||||||
| Marketing authorisation date | 23.09.2016 | ||||||||||||||||||||||||||
| Renewal date | 17.12.2020 | ||||||||||||||||||||||||||
| MA withdrawal date | 03.10.2024 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudine Stada | 600 mg / 300 mg | film-coated tablet | Marketed | STADA ARZNEIMITTEL AG |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 33761 | 08.07.2016 | Yes | No | 30, 90 (3 x 30), 30 | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | Abacavir/Lamivudine Stada | ||||||||||||||||||||||||||
| Marketing authorisation holder | STADA ARZNEIMITTEL AG | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1245 | ||||||||||||||||||||||||||
| Old product names | Abacavir/Lamivudine Pharos |
||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 30 Not marketed: 30, 90 (3 x 30) |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 30 (Nordic article number: 444643) Not marketed: 30, 90 (3 x 30) |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 33761 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 30 Not marketed: 30, 90 (3 x 30) |
||||||||||||||||||||||||||
| Marketing authorisation date | 08.07.2016 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abacavir/Lamivudine Teva | 600 mg / 300 mg | film-coated tablet | Not marketed | TEVA B.V. |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 33088 | 08.03.2018 | Yes | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | Abacavir/Lamivudine Teva | ||||||||||||||||||||||||||
| Marketing authorisation holder | TEVA B.V. | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 33088 | ||||||||||||||||||||||||||
| Marketing authorisation date | 23.06.2016 | ||||||||||||||||||||||||||
| MA withdrawal date | 08.03.2018 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abakavir/Lamivudin Mylan Pharma | 600 mg / 300 mg | film-coated tablet | Marketed | MYLAN AB |
Lamivudine
(+1)
|
J05AR02 lamivudine and abacavir | No | No | No | No | Yes | No | 33936 | 11.10.2018 | Yes | No | 30, 30, 30 x 1, 90 (30 x 3), 90 | No | No | Prescription |
No / No | No classification | Myyntilupa myönnetty | ||||
| Product name | Abakavir/Lamivudin Mylan Pharma | ||||||||||||||||||||||||||
| Marketing authorisation holder | MYLAN AB | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | J05AR02 lamivudine and abacavir, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Substitution group | 1245 | ||||||||||||||||||||||||||
| Old product names | Abakaviiri/Lamivudiini Vale Abakavir/Lamivudin Vale |
||||||||||||||||||||||||||
| Strength | 600 mg / 300 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 30 Not marketed: 30, 30 x 1, 90, 90 (30 x 3) |
||||||||||||||||||||||||||
| Pharmaceutical form | film-coated tablet | ||||||||||||||||||||||||||
| Active substances | Lamivudine, Abacavir sulfate | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 30 (Nordic article number: 380961) Not marketed: 30, 30 x 1, 90, 90 (30 x 3) |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | 33936 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 30 Not marketed: 30, 30 x 1, 90, 90 (30 x 3) |
||||||||||||||||||||||||||
| Marketing authorisation date | 11.10.2018 | ||||||||||||||||||||||||||
| Prescription terms | Hoidon saa aloittaa HIV-infektion hoitoon perehtynyt lääkäri. |
||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abalgin | 65 mg | capsule, hard | Not marketed | ALTERNOVA A/S | Dextropropoxyphene hydrochloride |
N02AC04 dextropropoxyphene | No | No | No | Yes | Yes | No | 1886 | 05.02.2010 | No | No | No | PA, PKV-lääke. Vain säilytettävällä reseptillä. | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | Abalgin | ||||||||||||||||||||||||||
| Marketing authorisation holder | ALTERNOVA A/S | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | N02AC04 dextropropoxyphene, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 65 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | capsule, hard | ||||||||||||||||||||||||||
| Active substances | Dextropropoxyphene hydrochloride | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 1886 | ||||||||||||||||||||||||||
| Marketing authorisation date | 07.07.1965 | ||||||||||||||||||||||||||
| Renewal date | 22.02.2008 | ||||||||||||||||||||||||||
| MA withdrawal date | 05.02.2010 | ||||||||||||||||||||||||||
| Affecting the ability to drive | Yes | ||||||||||||||||||||||||||
| PKV | PA, PKV-lääke. Vain säilytettävällä reseptillä. | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abalgin Retard | 150 mg | prolonged-release capsule, hard | Not marketed | ALTERNOVA A/S | Dextropropoxyphene hydrochloride |
N02AC04 dextropropoxyphene | No | No | No | Yes | Yes | No | 5297 | 05.02.2010 | No | No | No | PA, PKV-lääke. Vain säilytettävällä reseptillä. | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | Abalgin Retard | ||||||||||||||||||||||||||
| Marketing authorisation holder | ALTERNOVA A/S | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | N02AC04 dextropropoxyphene, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 150 mg | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | prolonged-release capsule, hard | ||||||||||||||||||||||||||
| Active substances | Dextropropoxyphene hydrochloride | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 5297 | ||||||||||||||||||||||||||
| Marketing authorisation date | 03.04.1968 | ||||||||||||||||||||||||||
| Renewal date | 22.02.2008 | ||||||||||||||||||||||||||
| MA withdrawal date | 05.02.2010 | ||||||||||||||||||||||||||
| Affecting the ability to drive | Yes | ||||||||||||||||||||||||||
| PKV | PA, PKV-lääke. Vain säilytettävällä reseptillä. | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| ABASAGLAR | 100 U/ml | solution for injection in cartridge | Marketed | ELI LILLY NEDERLAND B.V. | Insulin glargine |
A10AE04 insulin glargine | Yes | Biosimilaari/G006 | No | No | Yes | No | EU/1/14/944/003,009 | 09.09.2014 | No | No | 10 x 3 ml, 5 x 3 ml | No | No | Prescription |
No / No | Suitable for older adults | Myyntilupa myönnetty | ||||
| Product name | ABASAGLAR | ||||||||||||||||||||||||||
| Marketing authorisation holder | ELI LILLY NEDERLAND B.V. | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | A10AE04 insulin glargine, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Old product names | Abasria |
||||||||||||||||||||||||||
| Strength | 100 U/ml | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 5 x 3 ml Not marketed: 10 x 3 ml |
||||||||||||||||||||||||||
| Pharmaceutical form | solution for injection in cartridge | ||||||||||||||||||||||||||
| Active substances | Insulin glargine | ||||||||||||||||||||||||||
| Biosimilar status | Biosimilaari | ||||||||||||||||||||||||||
| Biosimilar group | G006 | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 5 x 3 ml (Nordic article number: 138421) Not marketed: 10 x 3 ml |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | |||||||||||||||||||||||||||
|
A (Insulin glargine) Suitable for older adults. Avoidance of hypoglycaemia is of paramount importance. (updated 27.9.2021) |
|||||||||||||||||||||||||||
| High-Risk Medicines Classification |
More information about the National High-Risk Medicines Classification |
||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | EU/1/14/944/003,009 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 5 x 3 ml Not marketed: 10 x 3 ml |
||||||||||||||||||||||||||
| Marketing authorisation date | 09.09.2014 | ||||||||||||||||||||||||||
| Renewal date | 25.07.2019 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | Yes | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| ABASAGLAR KwikPen | 100 U/ml | solution for injection in pre-filled pen | Marketed | ELI LILLY NEDERLAND B.V. | Insulin glargine |
A10AE04 insulin glargine | Yes | Biosimilaari/G006 | No | No | Yes | No | EU/1/14/944/007-008,012-013 | 09.09.2014 | No | No | 2 x (5 x 3 ml), 5 x 3 ml, 5 x 3 ml, 2 x (5 x 3 ml) | No | No | Prescription |
No / No | Suitable for older adults | Myyntilupa myönnetty | ||||
| Product name | ABASAGLAR KwikPen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ELI LILLY NEDERLAND B.V. | ||||||||||||||||||||||||||
| Shortage (by package size) |
No |
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | A10AE04 insulin glargine, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Old product names | Abasria Abasria Kwikpen Abasaglar Kwikpen Abasaglar |
||||||||||||||||||||||||||
| Strength | 100 U/ml | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription: 2 x (5 x 3 ml) Prescription: 5 x 3 ml Not marketed: 2 x (5 x 3 ml), 5 x 3 ml |
||||||||||||||||||||||||||
| Pharmaceutical form | solution for injection in pre-filled pen | ||||||||||||||||||||||||||
| Active substances | Insulin glargine | ||||||||||||||||||||||||||
| Biosimilar status | Biosimilaari | ||||||||||||||||||||||||||
| Biosimilar group | G006 | ||||||||||||||||||||||||||
| Package size (by package size) |
Marketed: 2 x (5 x 3 ml) (Nordic article number: 451991), 5 x 3 ml (Nordic article number: 448060) Not marketed: 2 x (5 x 3 ml), 5 x 3 ml |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | |||||||||||||||||||||||||||
|
A (Insulin glargine) Suitable for older adults. Avoidance of hypoglycaemia is of paramount importance. (updated 27.9.2021) |
|||||||||||||||||||||||||||
| High-Risk Medicines Classification |
More information about the National High-Risk Medicines Classification |
||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | EU/1/14/944/007-008,012-013 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Marketed: 2 x (5 x 3 ml), 5 x 3 ml Not marketed: 2 x (5 x 3 ml), 5 x 3 ml |
||||||||||||||||||||||||||
| Marketing authorisation date | 09.09.2014 | ||||||||||||||||||||||||||
| Renewal date | 25.07.2019 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | Yes | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| ABASAGLAR Tempo Pen | 100 U/ml | solution for injection in pre-filled pen | Not marketed | ELI LILLY NEDERLAND B.V. | Insulin glargine |
A10AE04 insulin glargine | Yes | Biosimilaari/G006 | No | No | Yes | No | EU/1/14/944/014-015 | 23.07.2020 | No | No | 5 x 3 ml, 2 x (5 x 3 ml) | No | No | Prescription |
No / No | Suitable for older adults | Myyntilupa myönnetty | ||||
| Product name | ABASAGLAR Tempo Pen | ||||||||||||||||||||||||||
| Marketing authorisation holder | ELI LILLY NEDERLAND B.V. | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | A10AE04 insulin glargine, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 100 U/ml | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Not marketed: 2 x (5 x 3 ml), 5 x 3 ml |
||||||||||||||||||||||||||
| Pharmaceutical form | solution for injection in pre-filled pen | ||||||||||||||||||||||||||
| Active substances | Insulin glargine | ||||||||||||||||||||||||||
| Biosimilar status | Biosimilaari | ||||||||||||||||||||||||||
| Biosimilar group | G006 | ||||||||||||||||||||||||||
| Package size (by package size) |
Not marketed: 2 x (5 x 3 ml), 5 x 3 ml |
||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | |||||||||||||||||||||||||||
|
A (Insulin glargine) Suitable for older adults. Avoidance of hypoglycaemia is of paramount importance. (updated 27.9.2021) |
|||||||||||||||||||||||||||
| High-Risk Medicines Classification |
More information about the National High-Risk Medicines Classification |
||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa myönnetty | ||||||||||||||||||||||||||
| MA-number | EU/1/14/944/014-015 | ||||||||||||||||||||||||||
| Marketed status (by package size) |
Not marketed: 2 x (5 x 3 ml), 5 x 3 ml |
||||||||||||||||||||||||||
| Marketing authorisation date | 23.07.2020 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | Yes | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abbodop | 1 mg/ml | solution for infusion | Not marketed | HOSPIRA ENTERPRISES BV | Dopamine hydrochloride |
C01CA04 dopamine | No | No | No | No | Yes | No | 10647 | 31.10.2009 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa peruuntunut | |||||
| Product name | Abbodop | ||||||||||||||||||||||||||
| Marketing authorisation holder | HOSPIRA ENTERPRISES BV | ||||||||||||||||||||||||||
| Shortage (by package size) |
No
|
||||||||||||||||||||||||||
| Link to package leaflet | |||||||||||||||||||||||||||
| Link to·summary of product characteristics | |||||||||||||||||||||||||||
| ATC code | C01CA04 dopamine, All medicinal products belonging to the ATC group | ||||||||||||||||||||||||||
| Strength | 1 mg/ml | ||||||||||||||||||||||||||
| Prescription status (by package size) |
Prescription |
||||||||||||||||||||||||||
| Pharmaceutical form | solution for infusion | ||||||||||||||||||||||||||
| Active substances | Dopamine hydrochloride | ||||||||||||||||||||||||||
| Type | Medicinal product for human use | ||||||||||||||||||||||||||
| Suitability for the elderly | No classification | ||||||||||||||||||||||||||
| Marketing authorisation status | Myyntilupa peruuntunut | ||||||||||||||||||||||||||
| MA-number | 10647 | ||||||||||||||||||||||||||
| Marketing authorisation date | 12.02.1992 | ||||||||||||||||||||||||||
| Renewal date | 27.08.2007 | ||||||||||||||||||||||||||
| MA withdrawal date | 31.10.2009 | ||||||||||||||||||||||||||
| Affecting the ability to drive | No | ||||||||||||||||||||||||||
| Biological medicinal products | No | ||||||||||||||||||||||||||
| Plasma-derived products | No | ||||||||||||||||||||||||||
| Parallel import | No | ||||||||||||||||||||||||||
| Parallel distribution | No | ||||||||||||||||||||||||||
| Abbodop | 2 mg/ml | solution for infusion | Not marketed | HOSPIRA ENTERPRISES BV | Dopamine hydrochloride |
C01CA04 dopamine | No | No | No | No | Yes | No | 10648 | 31.10.2009 | No | No | No | No | Prescription |
No / No | No classification | Myyntilupa | |||||